ABIOMED Company Profile (NASDAQ:ABMD)

About ABIOMED (NASDAQ:ABMD)

ABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Industry, Sector and Symbol:

Sector: Medical
Industry: Advanced Medical Equipment & Technology
Sub-Industry: Health Care Equipment
Symbol: NASDAQ:ABMD
CUSIP: 00365410
Web: www.abiomed.com

Capitalization:

Market Cap: $6.96373 billion
Outstanding Shares: 44,102,000

Average Prices:

50 Day Moving Avg: $152.81
200 Day Moving Avg: $138.79
52 Week Range: $95.14 - $159.80

P/E:

Trailing P/E Ratio: 91.81
Foreward P/E Ratio: 60.42
P/E Growth: 2.52

Sales & Book Value:

Annual Revenue: $474.78 million
Price / Sales: 14.59
Book Value: $12.86 per share
Price / Book: 12.22

Profitability:

EBIDTA: $110.92 million
Net Margins: 16.13%
Return on Equity: 13.03%
Return on Assets: 10.98%

Debt:

Debt-to-Equity Ratio: 0.03%
Current Ratio: 5.95%
Quick Ratio: 5.32%

Misc:

Average Volume: 297,928 shs.
Beta: 0.22
Short Ratio: 4.61

Frequently Asked Questions for ABIOMED (NASDAQ:ABMD)

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) announced its quarterly earnings results on Thursday, July, 27th. The company reported $0.45 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.42 by $0.03. The company had revenue of $132.47 million for the quarter, compared to analyst estimates of $130.83 million. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. ABIOMED's quarterly revenue was up 28.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.29 EPS. View ABIOMED's Earnings History.

When will ABIOMED make its next earnings announcement?

ABIOMED is scheduled to release their next quarterly earnings announcement on Wednesday, October, 25th 2017. View Earnings Estimates for ABIOMED.

Where is ABIOMED's stock going? Where will ABIOMED's stock price be in 2017?

7 brokerages have issued 12-month target prices for ABIOMED's stock. Their forecasts range from $140.00 to $175.00. On average, they expect ABIOMED's stock price to reach $157.50 in the next year. View Analyst Ratings for ABIOMED.

Who are some of ABIOMED's key competitors?

Some companies that are related to ABIOMED include ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL), Accelerate Diagnostics (AXDX), Natus Medical Incorporated (BABY), Mazor Robotics (MZOR), ABAXIS (ABAX), Luminex Corporation (LMNX), LeMaitre Vascular (LMAT), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), Accuray Incorporated (ARAY), ViewRay (VRAY) and Corindus Vascular Robotics (CVRS).

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:

Michael R. Minogue, Chairman of the Board, President, Chief Executive Officer
Ian McLeod, Principal Financial Officer, Principal Accounting Officer, Vice President, Controller
David M. Weber, Chief Operating Officer
William J. Bolt, Senior Vice President, Global Quality, Regulatory and Clinical Operations
Andrew J. Greenfield, Vice President, General Manager - Global Marketing
Michael G. Howley, Vice President, General Manager - Global Sales and Marketing
Dorothy E. Puhy, Lead Independent Director
Jeannine M. Rivet, Independent Director
Eric A. Rose M.D., Independent Director
Martin P. Sutter, Independent Director

Who owns ABIOMED stock?

ABIOMED's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include PRIMECAP MANAGEMENT COMPANY (9.85%), BlackRock Inc. (7.69%), Vanguard Group Inc. (7.56%), Baillie Gifford & Co. (4.49%), Palo Alto Investors LLC (4.45%) and State Street Corp (2.44%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Who sold ABIOMED stock? Who is selling ABIOMED stock?

ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Voya Investment Management LLC, Jackson Square Partners LLC, Russell Investments Group Ltd., William Blair Investment Management LLC, Macquarie Group Ltd., Arrowstreet Capital Limited Partnership and Marshall Wace North America L.P.. Company insiders that have sold ABIOMED stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Michael G Howley, Michael R Minogue and Paul Thomas. View Insider Buying and Selling for ABIOMED.

Who bought ABIOMED stock? Who is buying ABIOMED stock?

ABIOMED's stock was acquired by a variety of institutional investors in the last quarter, including Koch Industries Inc., Baillie Gifford & Co., FMR LLC, Renaissance Technologies LLC, Frontier Capital Management Co. LLC, State Treasurer State of Michigan, BlackRock Inc. and Castleark Management LLC. View Insider Buying and Selling for ABIOMED.

How do I buy ABIOMED stock?

Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABIOMED stock can currently be purchased for approximately $157.10.

MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		259 (Vote Outperform)
Underperform Votes:		178 (Vote Underperform)
Total Votes:		437

MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Consensus Ratings for ABIOMED (NASDAQ:ABMD) (How are Consensus Ratings Calculated?)

Ratings Breakdown:	1 Hold Rating, 6 Buy Ratings
Consensus Rating:	Buy (Score: 2.86)
Consensus Price Target:	$157.50 (0.25% upside)

Analysts' Ratings History for ABIOMED (NASDAQ:ABMD)

Show:

Date	Firm	Action	Rating	Price Target	Impact on Share Price
8/29/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$160.00	Low
8/29/2017	Jefferies Group LLC	Reiterated Rating	Buy	$175.00	Low
7/10/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$135.00 -> $140.00	Low
6/8/2017	William Blair	Reiterated Rating	Outperform -> Outperform		Low
3/30/2017	Leerink Swann	Boost Price Target	Outperform	$140.00 -> $150.00	Low
1/8/2017	BTIG Research	Reiterated Rating	Buy	$170.00	N/A
12/6/2016	Guggenheim	Initiated Coverage	Buy	$150.00	N/A
4/10/2016	Benchmark Co.	Reiterated Rating	Buy	$145.00	N/A
10/30/2015	Raymond James Financial, Inc.	Upgrade	Market Perform -> Outperform	$85.00	N/A
10/29/2015	Sterne Agee CRT	Reiterated Rating	Buy		N/A

(Data available from 9/20/2015 forward)

Earnings History for ABIOMED (NASDAQ:ABMD)

Earnings by Quarter for ABIOMED (NASDAQ:ABMD)

Earnings History by Quarter for ABIOMED (NASDAQ ABMD)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/25/2017		$0.36					N/A
7/27/2017	Q1 2018	$0.42	$0.45	$130.83 million	$132.47 million	View	N/A
5/4/2017	Q4 2017	$0.33	$0.33	$122.82 million	$124.68 million	View	Listen
1/26/2017	Q317	$0.29	$0.34	$112.71 million	$114.70 million	View	Listen
10/27/2016	Q217	$0.24	$0.20	$103.16 million	$103.00 million	View	Listen
7/28/2016	Q117	$0.23	$0.29	$97.23 million	$103.00 million	View	Listen
5/3/2016	Q416	$0.19	$0.24	$90.52 million	$94.00 million	View	N/A
2/4/2016	Q316	$0.15	$0.23	$80.04 million	$85.80 million	View	Listen
10/29/2015	Q2	$0.13	$0.17	$74.56 million	$76.30 million	View	Listen
8/4/2015	Q116	$0.08	$0.20	$66.27 million	$73.40 million	View	N/A
5/5/2015	Q415	$0.12	$0.28	$62.55 million	$67.60 million	View	N/A
1/27/2015	Q315	$0.03	$0.30	$53.20 million	$62.00 million	View	N/A
10/30/2014	Q215	$0.02	$0.09	$48.80 million	$51.80 million	View	N/A
7/31/2014	Q115	$0.02	($0.04)	$297.10 million	$48.80 million	View	N/A
5/1/2014	Q414	$0.09	$0.09	$50.93 million	$50.40 million	View	N/A
1/31/2014	Q314	$0.05	$0.11	$46.00 million	$46.20 million	View	N/A
11/6/2013	Q214	$0.03	$0.03	$43.75 million	$44.30 million	View	N/A
8/1/2013	Q1 2014	$0.06	($0.04)	$42.93 million	$42.70 million	View	N/A
5/2/2013	Q4 2013	$0.08	$0.09	$41.87 million	$43.70 million	View	N/A
2/6/2013	Q3 2013	$0.07	$0.07	$38.04 million	$38.30 million	View	N/A
11/1/2012	Q213	$0.05	$0.20	$37.47 million	$37.40 million	View	N/A
8/2/2012		$0.10	$0.16			View	N/A
5/16/2012		$0.07	$0.07			View	N/A
2/3/2012		($0.01)	$0.07			View	N/A
11/3/2011		($0.09)	$0.02			View	N/A
8/4/2011		($0.06)	($0.03)			View	N/A
5/18/2011		($0.04)	($0.05)			View	N/A
2/3/2011		($0.09)	($0.02)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for ABIOMED (NASDAQ:ABMD)

2017 EPS Consensus Estimate: $1.09
2018 EPS Consensus Estimate: $1.78
2019 EPS Consensus Estimate: $2.47

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2017	6	$0.20	$0.29	$0.24
Q2 2017	3	$0.22	$0.24	$0.23
Q3 2017	3	$0.29	$0.31	$0.30
Q4 2017	2	$0.32	$0.32	$0.32
Q1 2018	3	$0.40	$0.43	$0.41
Q2 2018	3	$0.32	$0.38	$0.35
Q3 2018	3	$0.46	$0.50	$0.48
Q4 2018	3	$0.50	$0.61	$0.55
Q1 2019	2	$0.58	$0.61	$0.60
Q2 2019	1	$0.51	$0.51	$0.51
Q3 2019	1	$0.63	$0.63	$0.63
Q4 2019	2	$0.65	$0.82	$0.74

(Data provided by Zacks Investment Research)

Dividend History for ABIOMED (NASDAQ:ABMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading and Institutional Ownership History for ABIOMED (NASDAQ:ABMD)

Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 89.69%

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/30/2017	Eric A Md Rose	Director	Sell	982	$145.17	$142,556.94
8/24/2017	Eric A Md Rose	Director	Sell	23,018	$151.09	$3,477,789.62
8/15/2017	Paul Thomas	Director	Sell	10,000	$154.71	$1,547,100.00
7/31/2017	David M Weber	COO	Sell	16,500	$147.63	$2,435,895.00
5/16/2017	Michael G Howley	VP	Sell	18,279	$133.56	$2,441,343.24
5/8/2017	David M Weber	COO	Sell	21,250	$130.89	$2,781,412.50
5/8/2017	Dorothy E Puhy	Director	Sell	13,500	$131.12	$1,770,120.00
5/8/2017	Michael G Howley	VP	Sell	600	$132.84	$79,704.00
3/17/2017	Andrew J Greenfield	VP	Sell	10,000	$124.00	$1,240,000.00
12/13/2016	Dorothy E Puhy	Director	Sell	8,000	$120.00	$960,000.00
11/30/2016	Eric A Md Rose	Director	Sell	8,000	$110.81	$886,480.00
9/22/2016	Michael R Minogue	CEO	Sell	28,039	$127.07	$3,562,915.73
9/21/2016	Michael R Minogue	CEO	Sell	5,034	$127.07	$639,670.38
9/19/2016	Michael R Minogue	CEO	Sell	58,710	$127.00	$7,456,170.00
8/15/2016	Dorothy E Puhy	Director	Sell	5,160	$123.94	$639,530.40
8/10/2016	Dorothy E Puhy	Director	Sell	3,900	$122.31	$477,009.00
8/8/2016	Michael G Howley	VP	Sell	17,853	$119.20	$2,128,077.60
8/1/2016	Henri A Termeer	Director	Sell	25,866	$118.70	$3,070,294.20
6/29/2016	Michael G Howley	VP	Sell	10,000	$106.58	$1,065,800.00
6/7/2016	Andrew J Greenfield	VP	Sell	9,000	$104.16	$937,440.00
5/23/2016	David M Weber	COO	Sell	4,342	$96.97	$421,043.74
5/16/2016	David M Weber	COO	Sell	5,604	$94.56	$529,914.24
5/6/2016	David M Weber	COO	Sell	2,145	$93.82	$201,243.90
5/5/2016	David M Weber	COO	Sell	52,000	$95.27	$4,954,040.00
5/5/2016	Paul Thomas	Director	Sell	7,500	$95.14	$713,550.00
4/18/2016	Andrew J Greenfield	VP	Sell	10,000	$99.10	$991,000.00
4/13/2016	Michael G Howley	VP	Sell	9,800	$98.64	$966,672.00
4/8/2016	Michael G Howley	VP	Sell	200	$98.80	$19,760.00
4/1/2016	Dorothy E Puhy	Director	Sell	10,000	$95.02	$950,200.00
3/31/2016	Andrew J Greenfield	VP	Sell	15,000	$94.11	$1,411,650.00
3/24/2016	David M Weber	COO	Sell	5,235	$89.93	$470,783.55
3/22/2016	Andrew J Greenfield	VP	Sell	24,800	$89.06	$2,208,688.00
3/22/2016	Dorothy E Puhy	Director	Sell	10,000	$90.30	$903,000.00
3/21/2016	Andrew J Greenfield	VP	Sell	19,572	$89.07	$1,743,278.04
3/10/2016	Andrew J Greenfield	VP	Sell	200	$89.00	$17,800.00
3/8/2016	David M Weber	COO	Sell	17,521	$85.20	$1,492,789.20
3/8/2016	William J Bolt	SVP	Sell	17,510	$85.19	$1,491,676.90
3/7/2016	David M Weber	COO	Sell	8,111	$85.21	$691,138.31
3/7/2016	Dorothy E Puhy	Director	Sell	4,000	$85.00	$340,000.00
3/7/2016	William J Bolt	SVP	Sell	7,987	$85.20	$680,492.40
2/8/2016	Dorothy E. Puhy	Director	Sell	4,000	$80.47	$321,880.00
8/19/2015	Michael R. Minogue	CEO	Sell	146,800	$104.87	$15,394,916.00
8/17/2015	Dorothy E Puhy	Director	Sell	2,580	$103.91	$268,087.80
8/14/2015	Dorothy E Puhy	Director	Sell	2,580	$105.27	$271,596.60
7/17/2015	Michael G Howley	VP	Sell	21,295	$70.00	$1,490,650.00
6/15/2015	Andrew J Greenfield	VP	Sell	3,185	$65.00	$207,025.00
5/29/2015	Martin P Sutter	Director	Buy	7,500	$60.17	$451,275.00
5/27/2015	David M Weber	COO	Sell	17,968	$60.77	$1,091,915.36
5/12/2015	Michael G Howley	VP	Sell	17,353	$66.47	$1,153,453.91
5/7/2015	Andrew J Greenfield	VP	Sell	3,500	$71.00	$248,500.00
5/7/2015	Robert Bowen	CFO	Sell	2,372	$71.52	$169,645.44
5/6/2015	David M Weber	COO	Sell	1,605	$73.72	$118,320.60
5/6/2015	Michael R Minogue	CEO	Sell	8,840	$73.12	$646,380.80
5/6/2015	William J Bolt	SVP	Sell	1,750	$74.27	$129,972.50
3/23/2015	David M Weber	COO	Sell	3,765	$71.08	$267,616.20
10/31/2014	Andrew J Greenfield	VP	Sell	15,000	$31.90	$478,500.00
10/31/2014	Michael R Minogue	CEO	Sell	164,000	$31.14	$5,106,960.00
7/28/2014	Michael R Minogue	CEO	Sell	82,383	$26.30	$2,166,672.90
5/27/2014	Andrew J Greenfield	VP	Sell	7,026	$21.10	$148,248.60
5/27/2014	David M Weber	COO	Sell	10,172	$21.11	$214,730.92
5/27/2014	Michael R Minogue	CEO	Sell	90,001	$21.19	$1,907,121.19
5/27/2014	Robert Bowen	CFO	Sell	6,820	$21.11	$143,970.20
5/27/2014	William J Bolt	SVP	Sell	8,029	$21.10	$169,411.90
5/15/2014	David Weber	COO	Sell	1,425	$20.94	$29,839.50
5/15/2014	Michael Howley	VP	Sell	1,267	$20.94	$26,530.98
5/15/2014	Michael Minogue	CEO	Sell	4,433	$20.94	$92,827.02
5/15/2014	William Bolt	SVP	Sell	1,110	$20.94	$23,243.40
1/10/2014	Robert Bowen	CFO	Sell	37,500	$30.00	$1,125,000.00
9/3/2013	David Weber	COO	Sell	6,500	$24.00	$156,000.00
9/3/2013	William Bolt	SVP	Sell	20,000	$24.00	$480,000.00
8/14/2013	William Bolt	SVP	Sell	21,534	$23.35	$502,818.90
8/13/2013	David Weber	COO	Sell	4,400	$23.00	$101,200.00
8/13/2013	Michael Howley	VP	Sell	8,400	$23.00	$193,200.00
8/5/2013	David Weber	COO	Sell	7,100	$22.90	$162,590.00
8/5/2013	Michael Howley	VP	Sell	1,600	$23.03	$36,848.00
8/5/2013	Robert Bowen	CFO	Sell	2,235	$22.64	$50,600.40
8/5/2013	W Gerald Austen	Director	Sell	8,000	$22.85	$182,800.00
8/5/2013	William Bolt	SVP	Sell	20,166	$22.70	$457,768.20
7/31/2013	Michael R Minogue	CEO	Sell	36,500	$25.04	$913,960.00
7/17/2013	Michael G Howley	VP	Sell	10,000	$24.45	$244,500.00
7/15/2013	Robert Bowen	CFO	Sell	40,786	$23.50	$958,471.00
7/11/2013	Robert Bowen	CFO	Sell	1,499	$23.50	$35,226.50
6/4/2013	David M Weber	COO	Sell	6,519	$21.20	$138,202.80
6/4/2013	Michael G Howley	VP	Sell	3,881	$21.20	$82,277.20
6/4/2013	Michael R Minogue	CEO	Sell	17,667	$21.23	$375,070.41
6/4/2013	Robert Bowen	CFO	Sell	5,298	$21.20	$112,317.60
6/4/2013	William J Bolt	SVP	Sell	4,967	$21.20	$105,300.40
5/29/2013	Michael R Minogue	CEO	Sell	58,833	$21.83	$1,284,324.39
5/28/2013	David M Weber	COO	Sell	6,018	$22.18	$133,479.24
5/28/2013	Michael G Howley	VP	Sell	5,476	$22.18	$121,457.68
5/28/2013	Robert Bowen	CFO	Sell	5,102	$22.18	$113,162.36
5/28/2013	William J Bolt	SVP	Sell	4,629	$22.18	$102,671.22
5/23/2013	Andrew J Greenfield	VP	Sell	1,666	$21.63	$36,035.58
5/23/2013	Michael R Minogue	CEO	Sell	5,666	$21.62	$122,498.92
5/17/2013	Robert Bowen	CFO	Sell	2,715	$23.50	$63,802.50
5/9/2013	Michael R Minogue	CEO	Sell	20,000	$21.00	$420,000.00
5/7/2013	Henri A Termeer	Director	Buy	100,000	$19.86	$1,986,000.00
2/25/2013	Henri A Termeer	Director	Buy	100,000	$14.98	$1,498,000.00

(Data available from 1/1/2013 forward)

Headline Trends for ABIOMED (NASDAQ:ABMD) Latest Headlines for ABIOMED (NASDAQ:ABMD)

Source:

Date	Headline
	Zacks: Brokerages Anticipate ABIOMED, Inc. (ABMD) Will Announce Quarterly Sales of $130.37 Million www.americanbankingnews.com - September 13 at 3:56 AM
	ABIOMED, Inc. (ABMD) Receives Consensus Recommendation of "Buy" from Analysts www.americanbankingnews.com - September 12 at 9:03 AM
	$0.37 Earnings Per Share Expected for ABIOMED, Inc. (ABMD) This Quarter www.americanbankingnews.com - September 11 at 8:16 PM
	ABMD Crosses Above Average Analyst Target www.nasdaq.com - September 11 at 3:47 PM
	Biolase (BIOL) vs. ABIOMED (ABMD) Head-To-Head Contrast www.americanbankingnews.com - September 2 at 4:10 PM
	ABIOMED, Inc. – Value Analysis (NASDAQ:ABMD) : September 2, 2017 finance.yahoo.com - September 2 at 1:54 AM
	ABIOMED, Inc. (ABMD) Director Eric A. Md Rose Sells 982 Shares www.americanbankingnews.com - September 1 at 8:30 PM
	Harvard Bioscience (HBIO) & ABIOMED (ABMD) Critical Contrast www.americanbankingnews.com - August 30 at 4:26 PM
	ABIOMED, Inc. breached its 50 day moving average in a Bearish Manner : ABMD-US : August 30, 2017 finance.yahoo.com - August 30 at 3:21 PM
	ABIOMED's (ABMD) Buy Rating Reiterated at Piper Jaffray Companies www.americanbankingnews.com - August 30 at 2:28 PM
	Abiomed searches for new CFO after Tomsicek resigns - MarketWatch www.marketwatch.com - August 30 at 1:49 AM
	ABIOMED, Inc. (ABMD) Rating Reiterated by Jefferies Group LLC www.americanbankingnews.com - August 29 at 1:04 PM
	Abiomed (ABMD) CFO Resigns to Pursue Other Interests www.streetinsider.com - August 29 at 1:38 AM
	Abiomed (ABMD) CFO Resigns to Pursue Other Interests - StreetInsider.com www.streetinsider.com - August 28 at 8:37 PM
	Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former Chief Financial Officer as Consultant finance.yahoo.com - August 28 at 8:37 PM
	Abiomed searches for new CFO after Tomsicek resigns finance.yahoo.com - August 28 at 8:37 PM
	Eric A. Md Rose Sells 23,018 Shares of ABIOMED, Inc. (ABMD) Stock www.americanbankingnews.com - August 28 at 7:20 PM
	ABIOMED, Inc. (ABMD) Downgraded by BidaskClub to "Hold" www.americanbankingnews.com - August 26 at 7:52 PM
	ABIOMED, Inc. (ABMD) Expected to Post Quarterly Sales of $130.37 Million www.americanbankingnews.com - August 26 at 4:00 PM
	Head to Head Survey: ABIOMED (ABMD) vs. PerkinElmer (PKI) www.americanbankingnews.com - August 25 at 10:36 AM
	ABIOMED, Inc. (ABMD) Given Consensus Recommendation of "Buy" by Analysts www.americanbankingnews.com - August 18 at 8:38 AM
	ABIOMED, Inc. (ABMD) Director Sells $1,547,100.00 in Stock www.americanbankingnews.com - August 17 at 7:38 PM
	ETFs with exposure to ABIOMED, Inc. : August 15, 2017 finance.yahoo.com - August 15 at 3:35 PM
	IHS Markit Score Update: Drop in demand for ETFs holding Abiomed Inc is a negative sign for its shares finance.yahoo.com - August 12 at 1:41 AM
	Why ABIOMED (ABMD) Could Be Positioned for a Surge finance.yahoo.com - August 10 at 4:49 PM
	See what the IHS Markit Score report has to say about Abiomed Inc. finance.yahoo.com - August 9 at 8:36 PM
	ABIOMED, Inc. (ABMD) Downgraded by Zacks Investment Research to Hold www.americanbankingnews.com - August 7 at 1:42 PM
	$130.37 Million in Sales Expected for ABIOMED, Inc. (ABMD) This Quarter www.americanbankingnews.com - August 7 at 7:44 AM
	ABIOMED, Inc. (NASDAQ:ABMD) Stock Rating Reaffirmed by Jefferies Group LLC www.americanbankingnews.com - August 6 at 8:12 AM
	Brokerages Expect ABIOMED, Inc. (NASDAQ:ABMD) to Announce $0.37 EPS www.americanbankingnews.com - August 5 at 10:38 PM
	PerkinElmer (PKI) Meets Q2 Earnings, Raises '17 Guidance finance.yahoo.com - August 4 at 3:23 PM
	Allscripts (MDRX) Meets Q2 Earnings Estimates, View Upbeat finance.yahoo.com - August 4 at 3:23 PM
	ABIOMED, Inc. :ABMD-US: Earnings Analysis: Q1, 2018 By the Numbers : August 2, 2017 finance.yahoo.com - August 2 at 8:22 PM
	ABIOMED, Inc. (NASDAQ:ABMD) COO Sells $2,435,895.00 in Stock www.americanbankingnews.com - August 2 at 7:26 PM
	DexCom (DXCM) Q2 Loss Narrower Than Expected, Revenues Beat finance.yahoo.com - August 2 at 3:19 PM
	Cardinal Health (CAH) Q4 Earnings Beat Estimates, Rise Y/Y finance.yahoo.com - August 2 at 3:19 PM
	Quality Systems (QSII) Beats on Q1 Earnings, Revenues finance.yahoo.com - August 2 at 3:19 PM
	Q4 2018 EPS Estimates for ABIOMED, Inc. Lifted by Leerink Swann (NASDAQ:ABMD) www.americanbankingnews.com - July 31 at 10:06 AM
	William Blair Research Analysts Lift Earnings Estimates for ABIOMED, Inc. (NASDAQ:ABMD) www.americanbankingnews.com - July 31 at 9:04 AM
	Abiomed (ABMD) Q1 Earnings and Revenues Beat Estimates - Nasdaq www.nasdaq.com - July 28 at 3:39 PM
	Abiomed (ABMD) Q1 Earnings and Revenues Beat Estimates finance.yahoo.com - July 28 at 3:39 PM
	Abiomed, Inc. Starts Its Fiscal Year on a High Note www.fool.com - July 28 at 9:20 AM
	Investor Network: ABIOMED, Inc. to Host Earnings Call finance.yahoo.com - July 27 at 8:33 PM
	Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year finance.yahoo.com - July 27 at 8:33 PM
	Edited Transcript of ABMD earnings conference call or presentation 27-Jul-17 12:00pm GMT finance.yahoo.com - July 27 at 8:33 PM
	ABIOMED, Inc. (ABMD) Issues Earnings Results www.americanbankingnews.com - July 27 at 4:59 PM
	Piper Jaffray Companies Reiterates "Overweight" Rating for ABIOMED, Inc. (NASDAQ:ABMD) www.americanbankingnews.com - July 27 at 4:50 PM
	Abiomed beats Street 1Q forecasts finance.yahoo.com - July 27 at 3:24 PM
	Check Out 5 Profitable Stocks for Spectacular Gains - Nasdaq.com - Nasdaq www.nasdaq.com - July 26 at 3:17 PM
	ABIOMED Reaches Analyst Target Price - Nasdaq.com - Nasdaq www.nasdaq.com - July 26 at 3:17 PM